"We chose to study veterans because of the prevalence of debilitating PTSD among this population," said Dr. Marcel Bonn-Miller, the coordinating principal investigator on Sisley's team. "That said, we believe the findings from this work will generalize to individuals with PTSD more broadly."

The development is being hailed as one of the most important forward movements in the medical cannabis space to date in the United States.  "These studies are important to lift the stigma regarding the science of marijuana and begin to harness its benefits for those among us that need it most," said David Goldstein, CEO of PotBiotics, a cannabis research, robotics and artificial intelligence startup.

Scott Murphy, founder of Veterans for Safe Access and Compassionate Care was also enthusiastic about the impact of not only the study but also the expected results and data. "This study follows the rules established by the FDA to test the efficiency and safety of marijuana," he said. "It will allow veterans against marijuana or on the fence to know what millions of Americans and the world already know; marijuana is a safe alternative to pharmaceuticals."

Goldstein concurs that research is becoming less controversial and easier to gain approval.

"We're also seeing studies beget studies," he said. "In other words for every study that's done which shows strong medical properties of cannabis, there's more reason and pressure on the feds to increase opportunities research." 

If you liked this article you might like

Why the ECB's Latest Stimulus Disappointed Investors

Europe May Not Be a Tax Haven for U.S. Multinationals Much Longer

What's the Fallout From the T-Mobile Data Breach?

Europe Is Moving Closer to a New Round of Stimulus

Why European Stocks Still Have an Edge Over U.S. Shares